Profound Medical
PROF Healthcare Medical Devices
Profound Medical’s revenue for fiscal 2025 (year ended December 2025) was $16.1 million, up 50.7% from fiscal 2024. In the quarter to June 2026, revenue grew 12.3%, EPS grew 50.0%, free cash flow grew 17.5% and total debt rose 1.01%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
Follow PROF
Profound Medical (PROF) P/E ratio
Profound Medical has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 26 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| RXST RxSight, Inc. compare | n/m |
| QSI Quantum-Si Incorporated compare | n/m |
| TLSI TriSalus Life Sciences, Inc. compare | n/m |
| TMCI Treace Medical Concepts, Inc. compare | n/m |
| PROF Profound Medical | n/m |
| CATX Perspective Therapeutics, Inc. compare | n/m |
| LAB Standard BioTools Inc. compare | 2.9× |
| ELMD Electromed, Inc. compare | 20.0× |
| INFU InfuSystems Holdings, Inc. compare | 31.7× |
| Medical Devices industry median | 23.2× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)